Tvardi Therapeutics selects ulcerative colitis as initial indication for TTI-109 drug candidate
Tvardi Therapeutics said it selected ulcerative colitis (UC) as the initial disease indication for its oral STAT3 inhibitor TTI-109, following a completed Phase 1 healthy volunteer study. The company plans a UC clinical trial in 2027, subject to IND clearance and additional funding, and will host a key opinion leader webinar on August 19, 2026.
Key points
- Phase 1 healthy volunteer study showed placebo-adjusted reductions in immune cell subsets, including up to 76% reduction in Th17-associated populations.
- Company cites an addressable market of approximately $3 billion in the U.S. and $9 billion globally for UC.
- Planned UC trial start in 2027 is subject to IND clearance and additional funding, and the company has not stated amounts of additional funding needed.
- KOL webinar with Dr. Randy Longman is scheduled for Wednesday, August 19, 2026 at 11:00 AM ET.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.